compared to those with non-visible lesions, measured not only with DLQI but also with EQ-5D. In addition to demographic and … clinical variables, our model included health service utilisation variables related to psoriasis, and explained higher …

a comparison of adalimumab and etanercept for the treatment of psoriasis. IPD from trials of adalimumab versus placebo … trials. Symptom improvements of ≥75% and ≥90% (as measured by the Psoriasis Area and Severity Index [PASI] score at … psoriasis. …

cyclosporin in patients with chronic plaque psoriasis. Methods: A cost-effectiveness analysis was performed in parallel with a … plaque psoriasis inadequately controlled with topical treatment. Study perspective: The study was conducted from a societal … cyclosporin in patients with chronic plaque psoriasis. …

Psoriasis is a chronic, immune-mediated skin disorder that affects 1-3% of the general population worldwide. While … considered a non-life-threatening disease, psoriasis represents a social and financial burden for patients and the healthcare …, patients with a diagnosis of psoriasis usually need lifelong care, which also means a lifetime of expenses. We aimed to conduct …

interferon alpha-2a. In addition to safety and efficacy, the impact on health-related quality of life may be an important …

patients with non-small cell lung cancer (NSCLC) using the SF-36 and the EuroQOL questionnaires; 2. to evaluate the impact of … that affected quality of life and utility, the presence of metastasis had the greatest impact: patients with metastasis had …